|
86 Companies |
|
137 Products |
|
137 Products |
|
85 Mechanisms of Action |
|
4 Trials |
|
2019 News |
|
| «12...28293031323334353637383940» |
- |||| risperidone / Generic mfg.
Enrollment open: POC Study of Pipamperone Added to Stable Treatment With RIS or PAL in Chronic Schizophrenia (clinicaltrials.gov) - Mar 26, 2012
P2, N=60, Recruiting, Sponsor: PharmaNeuroBoost N.V.
Not yet recruiting --> Recruiting
- Enrollment change: Individually Based Psychosocial Rehabilitation for Older People With Serious Mental Illness (SMI) (clinicaltrials.gov) - Mar 25, 2012
P1, N=40, Active, not recruiting, Sponsor: Dartmouth-Hitchcock Medical Center
Not yet recruiting --> Recruiting N=70 --> 40
- Enrollment closed: Individually Based Psychosocial Rehabilitation for Older People With Serious Mental Illness (SMI) (clinicaltrials.gov) - Mar 25, 2012
P1, N=40, Active, not recruiting, Sponsor: Dartmouth-Hitchcock Medical Center
N=70 --> 40 Recruiting --> Active, not recruiting
- |||||||||| paliperidone extended release / Generic mfg.
New P3 trial: A Long-Term Study of JNS007ER in Patients With Schizophrenia (clinicaltrials.gov) - Mar 21, 2012
P3, N=228, Completed, Sponsor: Janssen Pharmaceutical K.K.
- Enrollment closed: Life Goals Behavioral Change to Improve Outcomes for Veterans With Serious Mental Illness (clinicaltrials.gov) - Mar 20, 2012
P=N/A, N=55, Active, not recruiting, Sponsor: Department of Veterans Affairs
Recruiting --> Active, not recruiting Enrolling by invitation --> Active, not recruiting
- ||| Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
New P1 trial: A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Paliperidone Palmitate in Patients With Schizophrenia (clinicaltrials.gov) - Mar 19, 2012
P1, N=325, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
- clozapine / Generic mfg.
Trial completion: fMRI Cholinergic Mechanisms in Schizophrenia (clinicaltrials.gov) - Mar 19, 2012
P=N/A, N=40, Completed, Sponsor: Department of Veterans Affairs
Enrolling by invitation --> Active, not recruiting Recruiting --> Completed
- famotidine / Generic mfg.
Enrollment change: Histamine H2 Antagonism as Adjuvant Therapy in Treatment Resistant Schizophrenia (clinicaltrials.gov) - Mar 18, 2012
P4, N=30, Completed, Sponsor: Jesper Ekelund
Recruiting --> Completed N=80 --> 30
- || New P3 trial: Transdiagnostic Group Treatments for Patients With Common Mental Disorders in Primary Health Care (clinicaltrials.gov) - Mar 18, 2012
P3, N=245, Completed, Sponsor: Karolinska Institutet
- famotidine / Generic mfg.
Trial completion: Histamine H2 Antagonism as Adjuvant Therapy in Treatment Resistant Schizophrenia (clinicaltrials.gov) - Mar 18, 2012
P4, N=30, Completed, Sponsor: Jesper Ekelund
N=80 --> 30 Recruiting --> Completed
- | encenicline (EVP-6124) / Forum Pharmaceuticals, Mitsubishi Tanabe
New P1 trial, Monotherapy: Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Schizophrenia (clinicaltrials.gov) - Mar 13, 2012
P1, N=21, Completed, Sponsor: EnVivo Pharmaceuticals, Inc.
- || aripiprazole / Generic mfg.
Trial completion: The Combination of Aripiprazole and Antidepressants in Psychotic Major Depression (clinicaltrials.gov) - Mar 13, 2012
P3, N=16, Completed, Sponsor: Massachusetts General Hospital
Recruiting --> Completed Active, not recruiting --> Completed
- New P2 trial: Therapeutic Efficacy of Transcranial Magnetic Stimulation in Schizophrenia (clinicaltrials.gov) - Mar 11, 2012
P2, N=14, Completed, Sponsor: Beth Israel Deaconess Medical Center
- Trial withdrawal: Change in Brain Bioenergetics in Bipolar Disorder in Response to Photic Stimulation (clinicaltrials.gov) - Mar 8, 2012
P=N/A, N=0, Withdrawn, Sponsor: Mclean Hospital
Active, not recruiting --> Completed Not yet recruiting --> Withdrawn
- Trial initiation date: Change in Brain Bioenergetics in Bipolar Disorder in Response to Photic Stimulation (clinicaltrials.gov) - Mar 8, 2012
P=N/A, N=0, Withdrawn, Sponsor: Mclean Hospital
Not yet recruiting --> Withdrawn Initiation date: Feb 2010 --> Jun 2010
- Enrollment change: Change in Brain Bioenergetics in Bipolar Disorder in Response to Photic Stimulation (clinicaltrials.gov) - Mar 8, 2012
P=N/A, N=0, Withdrawn, Sponsor: Mclean Hospital
Initiation date: Feb 2010 --> Jun 2010 N=30 --> 0
- olanzapine / Generic mfg., sertraline / Generic mfg.
Enrollment open: STOP-PD: Sustaining Remission of Psychotic Depression (clinicaltrials.gov) - Mar 6, 2012
P4, N=392, Recruiting, Sponsor: Weill Medical College of Cornell University
N=30 --> 0 Not yet recruiting --> Recruiting
- Trial completion: Magnetoencephalographic (MEG) Evidence for Novel Metaphor Processing Among Schizophrenic Patients (clinicaltrials.gov) - Mar 6, 2012
P=N/A, N=30, Completed, Sponsor: Shalvata Mental Health Center
Not yet recruiting --> Recruiting Recruiting --> Completed
- | ABT 354 / AbbVie
New P1 trial: A Positron Emission Tomography Study of SLV354 in Healthy Subjects and Subjects With Schizophrenia (clinicaltrials.gov) - Mar 4, 2012
P1, N=18, Completed, Sponsor: Abbott
- | Ingrezza (valbenazine) / Neurocrine, Mitsubishi Tanabe
Trial completion: NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (clinicaltrials.gov) - Mar 4, 2012
P2, N=37, Completed, Sponsor: Neurocrine Biosciences
Recruiting --> Completed Active, not recruiting --> Completed
- Trial completion: The Psychiatric Rehabilitation Approach to Weight Loss (clinicaltrials.gov) - Mar 4, 2012
P=N/A, N=133, Completed, Sponsor: University of Kansas
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Trial completion: Non-interventional Study: Real-life Use of Atypical Antipsychotics in Acute Inpatient Management of Schizophrenia (clinicaltrials.gov) - Mar 1, 2012
P=N/A, N=503, Completed, Sponsor: AstraZeneca
Active, not recruiting --> Completed Recruiting --> Completed
- Enrollment change: NIKOGEN: Social Cognition,Attentional Network and Nicotine Drug Dependency - A Pharmacological Clinical Trail (clinicaltrials.gov) - Feb 29, 2012
P1/2, N=101, Completed, Sponsor: Heinrich-Heine University, Duesseldorf
Recruiting --> Completed N=200 --> 101
- Trial completion: NIKOGEN: Social Cognition,Attentional Network and Nicotine Drug Dependency - A Pharmacological Clinical Trail (clinicaltrials.gov) - Feb 29, 2012
P1/2, N=101, Completed, Sponsor: Heinrich-Heine University, Duesseldorf
N=200 --> 101 Active, not recruiting --> Completed
- | zicronapine (Lu31-130) / Lundbeck
Trial completion: Study of the Safety, Tolerability, and Pharmacokinetics of Once Weekly Zicronapine in Patients With Schizophrenia (clinicaltrials.gov) - Feb 27, 2012
P2, N=42, Completed, Sponsor: H. Lundbeck A/S
Active, not recruiting --> Completed Active, not recruiting --> Completed
- haloperidol / Generic mfg.
Enrollment closed, Adherence: CAE-L: Customized Adherence Enhancement Plus Long-acting Injectable Antipsychotic (clinicaltrials.gov) - Feb 23, 2012
P=N/A, N=30, Active, not recruiting, Sponsor: University Hospitals of Cleveland
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||||||||| paliperidone extended release / Generic mfg.
New P3 trial: A Study of Flexibly Dosed Paliperidone Extended Release Tablets in Participants With Schizophrenia (clinicaltrials.gov) - Feb 22, 2012
P3, N=405, Completed, Sponsor: Xian-Janssen Pharmaceutical Ltd.
- ||||| Korlym (mifepristone) / Corcept Therap
Enrollment change: A United States Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major Depression (clinicaltrials.gov) - Feb 13, 2012
P3, N=87, Completed, Sponsor: Corcept Therapeutics
Recruiting --> Active, not recruiting N=110 --> 87
- New P2 trial: Add-on Sodium Nitroprusside to Treatment as Usual in Schizophrenia (clinicaltrials.gov) - Feb 12, 2012
P2, N=20, Completed, Sponsor: University of Sao Paulo
- ||| Abilify Maintena (aripiprazole extended release) / Otsuka, Lundbeck
New P1 trial: Safety and Tolerability Trial of Aripiprazole IM Depot Treatment in Adult Subjects With Schizophrenia Stabilized on Oral Antipsychotics Other Than Aripiprazole (clinicaltrials.gov) - Feb 12, 2012
P1, N=60, Completed, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
- |||| aripiprazole / Generic mfg.
Trial completion: Efficacy and Safety of Aripiprazole in First Episode Psychosis (clinicaltrials.gov) - Feb 8, 2012
P4, N=55, Completed, Sponsor: Chonbuk National University Hospital
N=110 --> 87 Recruiting --> Completed
- Trial completion: Effect of Genotyping for CYP450 Polymorphisms Versus Intense Clinical Monitoring on Antipsychotic Drug Treatment (clinicaltrials.gov) - Feb 8, 2012
P=N/A, N=311, Completed, Sponsor: Gesche Jurgens
Recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
New P3 trial: A Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Patients With Schizophrenia (clinicaltrials.gov) - Feb 7, 2012
P3, N=511, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
- | PF-05180999 / Pfizer
New P1 trial: A Study to Assess the Relative Bioavailability of a Modified-Release Formulation of PF-05180999 (clinicaltrials.gov) - Feb 6, 2012
P1, N=12, Completed, Sponsor: Pfizer
- ||| Vraylar (cariprazine) / Mitsubishi Tanabe, Recordati, Gedeon Richter, AbbVie
Trial completion: Effects of Cariprazine on Cardiac Repolarization in Patients With Schizophrenia (clinicaltrials.gov) - Feb 6, 2012
P1, N=129, Completed, Sponsor: Forest Laboratories
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
New P4 trial: A Study to Evaluate the Effectiveness and Safety of Paliperidone Palmitate in Subjects With Acute Schizophrenia (clinicaltrials.gov) - Feb 5, 2012
P4, N=212, Completed, Sponsor: Johnson & Johnson Pte Ltd
- Enrollment change: Integrated Treatment to Persons With Mental Disorders and Co-occurring Substance Use Disorders (clinicaltrials.gov) - Jan 31, 2012
P=N/A, N=76, Completed, Sponsor: University of Oslo
Active, not recruiting --> Completed N=150 --> 76
- Enrollment open, HEOR: PULSAR: Effect of Sarcosine on Symptomatology, Quality of Life, Oxidative Stress and Glutamatergic Parameters in Schizophrenia (clinicaltrials.gov) - Jan 31, 2012
P2, N=70, Recruiting, Sponsor: Medical Universtity of Lodz
N=150 --> 76 Not yet recruiting --> Recruiting
- Trial completion: Acute Psychological Effects of High Intensity Exercise With Schizophrenia (clinicaltrials.gov) - Jan 31, 2012
P=N/A, N=60, Completed, Sponsor: Norwegian University of Science and Technology
Not yet recruiting --> Recruiting Recruiting --> Completed
- Trial completion: Integrated Treatment to Persons With Mental Disorders and Co-occurring Substance Use Disorders (clinicaltrials.gov) - Jan 31, 2012
P=N/A, N=76, Completed, Sponsor: University of Oslo
Recruiting --> Completed Recruiting --> Completed
- Enrollment closed: Facilitation of NMDA Receptor Function in Patients With Schizophrenia and Co-morbid Alcoholism (clinicaltrials.gov) - Jan 25, 2012
P2, N=46, Active, not recruiting, Sponsor: Elizabeth Ralevski
Recruiting --> Completed Recruiting --> Active, not recruiting
- New P1 trial: Pharmacological Approach to Improve the Outcome of Social Cognition Training (clinicaltrials.gov) - Jan 23, 2012
P1, N=27, Completed, Sponsor: VA Greater Los Angeles Healthcare System
- ||| Trial completion: Overcoming Psychiatric Barriers to the Treatment of Hepatitis C (clinicaltrials.gov) - Jan 23, 2012
P=N/A, N=101, Completed, Sponsor: University of North Carolina, Chapel Hill
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||||||||| risperidone / Generic mfg., blonanserin / Generic mfg.
New P3 trial: Efficiency Study to Investigate Blonanserin in Treatment of Schizophrenia When Compared With Risperidone (clinicaltrials.gov) - Jan 22, 2012
P3, N=267, Completed, Sponsor: Sumitomo Pharmaceutical (Suzhou) Co., Ltd.
- |||||||||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
New P3 trial, Head-to-Head: Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia (clinicaltrials.gov) - Jan 22, 2012
P3, N=1431, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
- Enrollment closed: Cognitive Training to Improve Work Outcomes in Severe Mental Illness (clinicaltrials.gov) - Jan 22, 2012
P2, N=152, Active, not recruiting, Sponsor: University of California, San Diego
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- acetylcysteine solution / Generic mfg.
Enrollment change: NAC: A Pilot Trial of Acute N-Acetylcysteine Effects on Working Memory and Other Cognitive Functions in Schizophrenia (clinicaltrials.gov) - Jan 19, 2012
P=N/A, N=26, Completed, Sponsor: Yale University
Recruiting --> Active, not recruiting N=20 --> 26
- acetylcysteine solution / Generic mfg.
Trial completion: NAC: A Pilot Trial of Acute N-Acetylcysteine Effects on Working Memory and Other Cognitive Functions in Schizophrenia (clinicaltrials.gov) - Jan 19, 2012
P=N/A, N=26, Completed, Sponsor: Yale University
N=20 --> 26 Enrolling by invitation --> Completed
- Enrollment change: Screening for Childhood-Onset Psychotic Disorders (clinicaltrials.gov) - Jan 18, 2012
P=N/A, N=250, Recruiting, Sponsor: National Institute of Mental Health (NIMH)
Enrolling by invitation --> Completed N=150 --> 250
- ||||||| lurasidone / Generic mfg.
Trial completion: Switch Ext: A Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder (clinicaltrials.gov) - Jan 16, 2012
P3, N=149, Completed, Sponsor: Sunovion
N=150 --> 250 Active, not recruiting --> Completed